107 results about "Platelet aggregation" patented technology

The invention provides a wound hemostasis device for the emergency department, and relates to the technical field of wound hemostasis. The wound hemostasis device for the emergency department comprises an inflatable hemostasis air bag, and a constant-temperature film bag is fixedly connected to the lower surface of the inflatable hemostasis air bag. During working, a second infusion pump is started and pumps water in a constant-temperature water storage tank through a second infusion pipeline, the water enters a constant-temperature film bag through a fourth infusion pipeline, the temperature of a wound is guaranteed, meanwhile, a first infusion pump is started, a first water valve on a first infusion pipeline is opened, and a second water valve on a second infusion pipeline is opened. Water in the constant-temperature film bag is pumped through the first liquid pumping pipeline, and finally the water enters the constant-temperature water storage tank, so that the water in the constant-temperature film bag is always in a constant-temperature state, the temperature is ensured to be close to the optimum point of thrombin reaction, platelet aggregation and fibrin formation can be accelerated, and the method is safe and efficient, can minimize tissue damage, and is suitable for clinical application. And the hemostasis speed is accelerated.

The present application relates to the technical field of resin preparation, and relates to a preparation method of an anticoagulant superabsorbent resin, which comprises the following steps: combining hydrolyzed tannic acid and nanocellulose through an oxidative coupling reaction, loading citric acid to obtain an anticoagulant compound; dissolving acrylic acid, sulfonated lignin, the anticoagulant compound, polylactic acid-diacrylate, azodicarboxamide, nanosilica and a photoinitiator in water to obtain a mixed solution; injecting the mixed solution into a microchannel reactor to perform a polymerization reaction under irradiation of pulsed ultraviolet light, so as to obtain a superabsorbent resin gel; immersing the superabsorbent resin gel in a polylactic acid-diacrylate solution, performing surface crosslinking through ultraviolet light irradiation, drying and grinding, so as to obtain anticoagulant superabsorbent resin particles; and the present application can inhibit platelet aggregation, delay the start of the coagulation cascade reaction, block the activation of coagulation factors, effectively prolong the blood clotting time, and provide a more sufficient liquid absorption window for the superabsorbent resin.

The invention discloses application of polyol nitrate in frostbite resistance, and belongs to the technical field of skin protection articles. The polyol nitrate is used as an active component of the ointment, and by slowly releasing nitric oxide and activating vascular endothelial nitric oxide synthase, spasm capillaries in the early stage of frostbite are effectively relaxed, platelet aggregation and thrombosis are inhibited, so that the pathological cascade reaction of frostbite is blocked, and the prevention and treatment effects on frostbite are remarkably improved. Compared with the prior art, the polyol nitrate and the ointment are scientific and reasonable in preparation method and safe and convenient to use, and a brand-new and effective solution is provided for prevention and treatment of skin frostbite in a cold environment.

The invention discloses application of compound resina draconis in preparation of a medicine for treating acute myocardial infarction. The compound resina draconis has the effects of resisting free radical oxidation and platelet aggregation, expanding coronary artery, inhibiting increase of myocardial enzymology CPK and LDH and reducing myocardial oxygen consumption, so that the myocardial infarction range is reduced, and myocardial ischemic ST segment elevation is improved; the compound is combined with aspirin for treating acute myocardial infarction, and the compound and aspirin have a synergistic effect, play a role in resisting platelet aggregation and inhibit synthesis of thromboxane A2, and show a good ischemic myocardial protection effect. Meanwhile, according to the technical scheme that the compound resina draconis is used independently or combined with aspirin, the application range of the medicine is widened, contribution is made for research and development of the medicine for relieving side effects caused by aspirin treatment, and the application prospect is good.

The invention discloses a medicine formula for preventing cerebral infarction and promoting rehabilitation and a preparation method thereof, and belongs to the technical field of preparation of medicines for preventing cerebral infarction, the medicine formula comprises the following raw materials by weight: 10-15 parts of flatstem milkvetch seed, 10-15 parts of dodder, 10-15 parts of tortoise plastron, 10-12 parts of red peony root, 6-9 parts of safflower, and 15-30 parts of red sage root. According to the invention, the flatstem milkvetch seed, the semen cuscutae and the tortoise plastron are used for nourishing liver and kidney, replenishing essence and benefiting marrow, so that the traditional Chinese medicine theory that kidney dominates bone marrow generation and brain is marrow sea is met, and brain function decline is improved from the source; meanwhile, the radix salviae miltiorrhizae, the radix paeoniae rubra and the flos carthami have the effects of promoting blood circulation to remove blood stasis, activating meridians to stop pain, effectively improving brain microcirculation, inhibiting platelet aggregation and reducing blood viscosity, and supplement each other to achieve the effects of strengthening the body resistance to eliminate pathogenic factors and treating both symptoms and root causes, so that the traditional Chinese medicine composition can be used for preventing cerebral infarction of high-risk groups and is also suitable for functional recovery in the rehabilitation period after cerebral infarction.

A series of sofalcone derivatives are provided.SOLUTION: A series of sofalcone derivatives provided by the present invention are, for example, compounds having a structure of formula (I), and have platelet aggregation inhibitory and antithrombotic effects. The sofalcone derivatives of the present invention are TxA2 receptor antagonists, have an inhibitory effect on platelet agglutination, and do not easily affect the hemostatic function. The present invention also provides a method for preparing the sofalcone derivative, and a method for using the sofalcone derivative for preventing or treating thrombotic diseases, or for inhibiting platelet aggregation.SELECTED DRAWING: None

The utility model discloses a hemostasis assist device for vascular surgery, which relates to the technical field of medical instruments, and comprises a fixing mechanism, a vascular surgery hemostasis mechanism is arranged in the fixing mechanism, the vascular surgery hemostasis mechanism comprises a knob, and the bottom of the knob is fixedly connected with a threaded column. According to the hemostasis mechanism for the vascular surgery department, during hemostasis, the periphery of a wound can be heated through the heating block across the replacement pad, the temperature of the periphery of the wound reaches 37-42 DEG C, activation of platelets can be accelerated to a certain extent at the temperature, energy metabolism of the platelets is accelerated within the temperature range, and the blood circulation is accelerated. The increase of the concentration of calcium ions in the blood platelets is an important signal of platelet activation, and the increased concentration of the calcium ions can promote the activation of glycoprotein receptors on platelet membranes, so that the binding capacity of the blood platelets and fibrinogen is enhanced, the aggregation of the blood platelets is accelerated, and the hemostasis speed is accelerated.

The invention provides a micro-fluidic chip for detecting platelet aggregation function, and relates to the technical field of platelet aggregation function detection.The micro-fluidic chip comprises a chip body, the chip body is provided with at least one group of detection parts, and each group of detection parts comprises a sample adding groove and at least one group of detection units; the detection unit comprises a coating runner and a reaction cavity; the inner wall of the coating flow channel is coated with an activating agent coating, and the length extending direction of the coating flow channel is inclined relative to the radial direction with the rotation center as the circle center, so that the proximal end and the distal end of the coating flow channel are located on different radial lines with the rotation center as the circle center respectively. Through the arrangement, local retention or dead zones are avoided, the detection efficiency is improved, the dissolution rate of the activator is effectively improved, the dissolution rate of an activator coating is more than 5 mu g / s, the activator is ensured to be fully dissolved, the error absolute value of the final concentration of the activator in a sample is less than 6%, the detection error is reduced, and the detection accuracy is improved.

The present application relates to the technical field of in vitro detection, and particularly relates to a platelet aggregation function detection reagent and application thereof.The platelet aggregation function detection reagent provided by the present application comprises a fibrin activator and an ADP reagent, the fibrin activator adopts a novel high-purity porcine dermal collagen polypeptide component Prionex, and the combination with glycine significantly improves the stability of the fibrin activator, the platelet inhibitor tirofiban is used in combination with PEG6000, the accuracy of the detection result is improved, and the sensitivity to the anti-platelet aggregation drug is improved; the ADP reagent adopts chitosan, the activity and stability are improved, and the ADP reagent can be widely applied to clinical diagnosis of platelet aggregation function.

Methods of inhibiting platelet activation and aggregation using peptide vaccines having binding specificity for the α subunit of the (Na++K+)-ATPase are provided, along with methods for inhibiting or preventing or treating thrombosis without causing bleeding.

The application belongs to the technical field of biotechnology, and particularly relates to a kind of snake venom polypeptide and application thereof.The snake venom polypeptide is polypeptide DACU-1, polypeptide DACU-2 or polypeptide DACU-3.The application provides a kind of new snake venom polypeptide, including three polypeptides, and the three polypeptides all have anti-platelet aggregation activity, and have the activity of inhibiting platelet aggregation under the stimulation of ADP, arachidonic acid, collagen, thrombin and other various activators, and have the potential to be developed into anti-platelet drugs, functional foods and health products.

The application discloses a preparation method and application of a paeonol derivative, and relates to the technical field of biomedicine. The paeonol derivative has the chemical structure as shown in the following formula: or. The paeonol extraction preparation method is simple, and the extraction rate of the paeonol is high. The prepared paeonol derivative has more excellent antioxidant activity, and the anti-inflammatory effect is enhanced, the anti-platelet aggregation effect is better, and the paeonol derivative also has good inhibitory activity on the occurrence and development of diabetic retinopathy.

The invention belongs to the technical field of biological medicine, and relates to an anticoagulant, in particular to an anticoagulant for a high-precision animal blood cell analyzer and application of the anticoagulant in leukocyte classification. The anticoagulant comprises a buffer and anticoagulation matrix component and an active component, wherein in every 100 mL of the anticoagulant, the buffer and anticoagulation matrix component formula comprises 1.5 to 2 g of citrate, 0.3 to 0.5 g of citric acid and 0.15 to 0.20 g of EDTA-K2 (Ethylene Diamine Tetraacetic Acid), and the active components comprise 0.08 to 0.10 g of low molecular weight enzymolysis carboxymethyl chitosan, 1.0 to 1.2 g of hydroxypropyl-beta-cyclodextrin, 10 to 15 mg of dipyridamole and 8 to 10 mg of aspirin. The anticoagulant effectively inhibits platelet activation, prevents platelet aggregation and leukocyte morphological deformation, realizes accurate identification in leukocyte five-classification, has a classification accuracy rate of 98%, and is suitable for veterinary clinical hematology examination and animal epidemic disease monitoring.

The invention relates to the technical field of medicinal chemistry, in particular to a novel carbamate fumarate, and a crystal form, an amorphous form and a preparation method thereof. The carbamate fumarate and the crystal form and the amorphous form thereof have high stability and solubility and low hygroscopicity, the medicinal performance is improved, the platelet aggregation resisting effect is better, the medicine effect is higher, and clinical application of the medicine is facilitated.

The application discloses a NO donor type ligustrazine derivative, a preparation method, a composition and application, and provides a NO donor type ligustrazine derivative and a preparation method thereof, and further provides a composition of different dosage forms prepared by mixing the NO donor type ligustrazine derivative or a pharmaceutically acceptable salt thereof and a pharmaceutical excipient, and application of the composition in preparation of a medicine for preventing or treating thromboembolic cardiovascular and cerebrovascular diseases and diseases caused by platelet aggregation.

Wound dressings and methods for treating a wound are provided. The wound dressing can have an environment-facing side that includes a biocompatible material having a polymer crosslinked with an antimicrobial effective amount of a NO-donor and a wound-facing side including a biocompatible resinous matrix and an antifibrinolytic agent. The wound dressing can promote fibrin formation and rapid platelet aggregation, and has antimicrobial properties. The dressing can be applied directly to the wound.

The present invention relates to a fluorescent probe based on a lanthanide metal organic framework, a preparation method and an application, and belongs to the field of nanomaterial technology. The fluorescent probe provided by the present invention is obtained by covalently cross-linking a lanthanide metal organic framework with a neutrophil elastin binding peptide and a P-selectin binding peptide, and the surface of the lanthanide metal organic framework is modified with a tetracyclic antibiotic and arginine. The fluorescent probe prepared by the present invention specifically targets activated platelets and neutrophils, does not affect cell survival rate, does not cause hemolysis of red blood cells, and can be applied to the preparation of diagnostic products for thrombotic diseases. The use of a fluorescent probe loaded with urokinase achieves stable and efficient delivery of urokinase, inhibits platelet aggregation, slows down blood clot contraction, has a good thrombolytic effect, and has the potential to be used in the preparation of drugs for the treatment of thrombotic diseases. The materials required for the present invention are easy to obtain, the preparation method is simple, and a new method is provided for the diagnosis and treatment of thrombotic diseases.

The invention provides a composition for improving the thrombolysis capacity of a human body, a preparation method and application thereof.The composition is prepared from, by weight, 5-30 parts of earthworm protein, 30-120 parts of hippophae rhamnoides total flavone extract, 50-150 parts of silymarin extract, 20-80 parts of maltodextrin and 15-60 parts of pregelatinized starch, the earthworm protein activates a fibrinolytic system to promote t-PA to release and dissolve thrombus, and the hippophae rhamnoides total flavone extract activates the fibrinolytic system to promote t-PA to release and dissolve thrombus; the hippophae rhamnoides total flavonoids regulate the ratio of PGI2 / TXA2 to inhibit platelet aggregation and reduce blood fat, the silymarin protects the liver function to enhance LDL-C metabolism clearing, the hippophae rhamnoides total flavonoids, the silymarin and the hippophae rhamnoides total flavonoids cooperate to form a thrombolysis-antithrombosis-metabolism regulation three-dimensional intervention system, a whole-course low-temperature mixing direct tabletting process is adopted

The application belongs to the technical field of biological medicine, and relates to an anticoagulant and application thereof in white blood cell classification for high-precision animal blood cell analyzers. The anticoagulant comprises two parts of buffer and anticoagulant matrix components and active components. In the anticoagulant, the buffer and anticoagulant matrix component formula comprises 1.5-2 g of citrate, 0.3-0.5 g of citric acid and 0.15-0.20 g of EDTA-K2 per 100 mL of the anticoagulant, and the active component comprises 0.08-0.10 g of low-molecular enzymatic hydrolysis carboxymethyl chitosan, 1.0-1.2 g of hydroxypropyl-beta-cyclodextrin, 10-15 mg of dipyridamole and 8-10 mg of aspirin. The anticoagulant effectively inhibits platelet activation, prevents platelet aggregation and white blood cell morphological deformation, accurately identifies in white blood cell five classification, and has a classification accuracy as high as 98%, and is suitable for veterinary clinical hematology examination and animal disease monitoring.

The invention discloses an application of a TBOA analogue in preparation of a kit for testing platelet stress self-regulating force, and the platelet stress self-regulating force is reflected by the aggregation degree of platelets after being intervened by the TBOA analogue. The application focuses on a new mechanism of platelet activation, that is, when platelets are stimulated by activators such as thrombin, normal reactions of activation and aggregation are driven and maintained by adjusting uptake of glutamic acid by EAATs. Due to the clear action mechanism, the application can provide indexes and methods with higher specificity in diagnosis, treatment and prognosis evaluation of thrombotic diseases, and the pertinence is extremely high. According to the application, the influence of the TBOA analogue on the platelet aggregation degree is utilized to test the stress self-regulating force of the platelet, and new clinical application of the TBOA analogue is developed.

The invention relates to the technical field of animal blood cell detection and analysis, in particular to a method for an animal blood cell analyzer to recognize platelet aggregation, which comprises the following steps: after the animal blood cell analyzer performs pretreatment and fluorescent staining on a blood sample in a white blood cell DIFF channel, acquiring three signals of blood cells through laser flow cytometry; two scatter diagrams are drawn according to the three signals, platelet aggregation particles are identified in a certain area range in the two scatter diagrams, when the number exceeds a threshold value, an alarm is given, and normal leukocytes cannot fall in the area. The good alarm function of the instrument provides more accurate prompts for clinical diagnosis, and clinical appropriate microscopic examination of platelets is facilitated. The cost is saved, extra testing is not needed, and the alarm function can be achieved in the leukocyte DIFF channel in the blood routine testing mode. The platelet aggregation region is identified, the influence of platelet aggregation on the total number of leukocytes is eliminated, and the leukocyte value is more accurate.

The invention discloses application of a compound in preparation of a medicine for treating or relieving ADPGK activation related concurrent diseases in chronic kidney diseases. The compound is found to be capable of effectively inhibiting the activity of ADPGK through computer virtual screening in combination with an in-vitro platelet activation experiment. In CKD patient and mouse models, the Z809269780 significantly reduces the glycolysis flux of platelets, lactic acid generation and RHOA lactylation level, thereby inhibiting the excessive activation and high reactivity of the platelets, and effectively relieving thrombosis events (such as platelet aggregation, adhesion, blood clot retraction and arterial thrombosis). Animal experiments show that intraperitoneal injection of the Z809269780 (10 mg / kg) has a good antithrombotic effect, and the Z809269780 does not show obvious toxicity under the dosage of 20 mg / kg. The invention provides a safe and effective novel targeted treatment strategy for preventing thrombotic complications of CKD patients.

The application discloses a sports nutrition food composition for blood vessel health and post-exercise recovery. Each 40g contains soybean protein isolate, whey protein, resistant dextrin, inulin, ginkgo biloba extract, hawthorn extract, grape seed extract, sea buckthorn peptide, natto powder (containing natto kinase), coenzyme Q10, natural vitamin E, vitamin C, bacillus subtilis DE111 and mineral probiotic premix. The application realizes blood vessel cleaning and post-exercise recovery through the synergy of multiple pathways such as direct thrombolytic effect of natto kinase, anti-platelet aggregation of ginkgo biloba / hawthorn / grape seed, protection of blood vessel endothelium by coenzyme Q10 / VE / VC, and regulation of intestinal tract by bacillus subtilis DE111. In-vitro thrombolysis experiment shows that the composition has clear fibrinolytic activity. All components meet the national standard of sports nutrition food, are safe and compliant, and are suitable for people with thrombosis risk and people who need blood vessel repair after high-intensity exercise.

The present application provides a kind of nereid polypeptide antithrombotic preparation, belong to the technical field of biopharmaceuticals.The present application finds that nereid plasmin polypeptide can inhibit the reaction of thrombin and fibrinogen to generate fibrin, thereby inhibiting the blood clotting reaction through in vitro test.Nereid plasmin polypeptide is determined for in vitro anti-platelet aggregation activity, and the inhibition rate of 640 μg / ml nereid plasmin polypeptide for anti-platelet aggregation is 75.68%, close to the inhibition effect of 1 mg / ml aspirin.The present application finds that nereid plasmin polypeptide group has the pharmacodynamic effect of reducing the weight of thrombus and the ratio of thrombus weight and length through nereid plasmin polypeptide antithrombotic effect test, has good antithrombotic effect, and can be used as nereid polypeptide antithrombotic preparation.

The invention belongs to the field of medicinal chemistry, and particularly relates to ligustrazine stilbene polyphenol aromatic acid ether compounds, pharmaceutically acceptable salts thereof, a preparation method thereof, a pharmaceutical composition and an application of the ligustrazine stilbene polyphenol aromatic acid ether compounds. The ligustrazine stilbene polyphenol aromatic acid ether compound and the pharmaceutically acceptable salt thereof have a remarkable anti-platelet aggregation effect, and can be used for preparing drugs for resisting platelet aggregation, preventing or treating cardiovascular diseases or treating or preventing thromboembolic diseases.

The present application relates to the technical field of platelet aggregation detection, and specifically discloses a clinical platelet aggregation detection carrier, which comprises an instrument body and further comprises: a detection assembly arranged inside the instrument body, which is used for detecting different types of samples of lipemia, anemia and normal blood and selecting centrifugal operation of the blood samples; the detection assembly can detect different types of samples of lipemia, anemia and normal blood, and can automatically indicate whether centrifugal operation of the blood is needed according to the types of the detected samples; through the sampling assembly, the blood samples at different layer depths can be automatically adjusted according to the lipemia, anemia and normal blood samples detected by the detection assembly; through the agent adding assembly, the amount of the added inducing agent can be automatically adjusted according to the sample amount taken by the sampling assembly, so that the concentration of the mixed inducing agent reaches the specified range, thereby improving the detection accuracy of the platelet aggregation degree.

The application relates to the technical field of medical treatment, and particularly discloses a preparation method of a physical thrombus for an animal model of a cerebrovascular disease, which comprises the following steps: S1, collecting fresh whole blood of an animal in a sterile manner, and rapidly transferring the whole blood into a pre-cooled syringe assembly within 60 seconds after collection; and S2, driving a piston of the syringe, so that the whole blood repeatedly passes through at least two needle heads with different inner diameters in a preset pulse variable speed mode in a constant temperature environment (37+ / -0.5 DEG C), wherein the whole blood is first injected through a needle head with a larger hole diameter, and finally injected through a needle head with a smaller hole diameter; the application fundamentally avoids the use of exogenous thrombin and other biochemical reagents, eliminates the interference of the biochemical reagents on a natural thrombus formation process and a final component, and directly and in situ activates an endogenous blood coagulation system by controlling physical shearing force suffered by the blood when passing through needle heads with different specifications, so as to promote platelet aggregation and fibrin network formation.

The utility model relates to the technical field of apical surgery, in particular to an in-vitro compression hemostasis device for apical surgery, which comprises placing cloth, adjustable elastic ropes are fixedly mounted on four sides of the placing cloth, an ice bag is arranged on one side of the placing cloth, gauze is wound on the outer sides of the placing bag and the ice bag, and the gauze is wound on the outer side of the placing cloth. A medical proof fabric is adhered to the interface of the gauze; according to the scheme, the placing cloth and the four adjustable elastic ropes are arranged, the ice bag can be placed on one side to wrap the ice bag, so that a patient can wear the ice bag conveniently, tight attachment of the ice bag and proper pressure can directly act on a bleeding part, the blood flow speed is reduced, platelet aggregation at a wound is promoted, thrombus is formed, bleeding is effectively stopped, and the patient can be prevented from being injured. The ice bag can be tightly attached to the body of a patient through the adjustable elastic rope and is not prone to slipping or shifting, and the wearing comfort and stability are improved.

The present application relates to a kind of preservative solution for prolonging the in vitro storage period of platelet and its preparation method, containing baicalin 4.50~6.00g, baicalein 3.00~3.40g, sodium citrate 1.50~2.00g, citric acid 0.20~0.50g, glucose 7.90~8.50g per liter of preservative solution, and the remaining component is distilled water.The preservative solution of the present application adds a certain proportion of baicalin and baicalein, and the composition has a synergistic effect on inhibiting platelet activation, protection and inhibition of platelet aggregation, can prolong the in vitro platelet normal temperature storage time, and the normal temperature storage time can reach 16d.